Personalized cancer vaccine shows potential in myeloma, solid tumors
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
A personalized cancer vaccine called PGV001 showed potential in combating several types of cancer, both solid tumors and blood malignancies like myeloma, in a…
The International Myeloma Foundation (IMF) has announced its 2nd annual Iceland Cycling Expedition (ICE), a seven-day endurance bike ride to raise funds for…
The use of dexamethasone alone may successfully treat the immune side effect cytokine release syndrome (CRS) in people with relapsed or refractory multiple…
This year’s Myeloma Action Month (MAM), which is observed each March, is focused on celebrating and sharing patient milestones to help call…
The presence of more than one high-risk genetic abnormality is associated with dramatically more aggressive multiple myeloma, a study reported. Its findings highlight the…
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Regeneron Pharmaceuticals seeking the approval of linvoseltamab to treat…
A first patient with relapsed/refractory multiple myeloma (RRMM) treated with CT0590, Carsgen Therapeutics’ CAR T-cell therapy, showed a complete response to the…
Researchers in Brazil have developed a large dataset of cells taken from the bone marrow of people with multiple myeloma (MM) and other blood…
Regulators in the European Union (EU) have approved Sarclisa (isatuximab) in combination with standard-of-care medications for adults newly diagnosed with multiple myeloma who…
Abbvie is teaming up with China-based company Simcere Zaiming to advance the development of SIM0500, Simcere’s experimental treatment for multiple myeloma that’s…